Status:
NOT_YET_RECRUITING
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Collaborating Sponsors:
Shanghai Clinical Research Center
Conditions:
GVHD
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis. In our previous study, the investigators demonstrated that the standard dose PTCY of 5...
Detailed Description
Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis. In our previous study, the investigators demonstrated that the standard dose PTCY of 5...
Eligibility Criteria
Inclusion
- Patients with hematological malignancies
- Patients undergo allogeneic stem cell transplantation from haplo-identical donors
- Patents with informed consent provided
Exclusion
- Patients with active infection ()bacteria, fungal or viral)
- Patients with liver, renal and cardiac dysfunction not suitable for undergoing allogeneic stem cell transplantation.
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT06000982
Start Date
October 1 2023
End Date
April 1 2026
Last Update
August 21 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Shenzhen People's Hospital
Shenzhen, GaungDong, China, 518000
2
Rui Jin Hospital
Shanghai, Shanghai Municipality, China, 200025